• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by InfuSystems Holdings Inc. (Amendment)

    11/29/23 5:08:28 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care
    Get the next $INFU alert in real time by email
    SC 13D/A 1 d10890974_13d-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    InfuSystem Holdings, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

     

    45685K102
    (CUSIP Number)

     

     

    Christopher Sansone

    c/o Sansone Advisors, LLC

    151 Bodman Place, Suite 100

    Red Bank, New Jersey 07701

    Telephone Number: (914) 715-8847

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

     

    May 16, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [X].

     

    _____________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

    CUSIP No. 45685K102    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Sansone Advisors, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   [_]
        (b)   [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      1,612,194  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      1,612,194  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,612,194  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      7.6%  

     

    14. TYPE OF REPORTING PERSON  
         
      OO  

     

     

    CUSIP No. 45685K102    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Sansone Capital Management, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   [_]
        (b)   [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      1,612,194  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      1,612,194  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,612,194  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      7.6%  

     

    14. TYPE OF REPORTING PERSON  
         
      OO  

     

     

    CUSIP No. 45685K102    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Sansone Partners, LP  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   [_]
        (b)   [_]
           

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      1,464,916  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      1,464,916  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,464,916  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      6.9%  

     

    14. TYPE OF REPORTING PERSON  
         
      PN  

     

     

    CUSIP No. 45685K102    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Christopher Sansone  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   [_]
        (b)   [_]
           

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF, OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      58,349  

     

    8. SHARED VOTING POWER  
         
      1,612,194  

     

    9. SOLE DISPOSITIVE POWER
         
      58,349  

     

    10. SHARED DISPOSITIVE POWER  
         
      1,612,194  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,670,543  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      7.9%  

     

    14. TYPE OF REPORTING PERSON  
         
      IN  

     

     

    CUSIP No. 45685K102    
         

     

    Item 1. Security and Issuer.  

     

      The name of the issuer is InfuSystem Holdings, Inc., a Delaware corporation (the "Issuer").  The address of the Issuer's principal executive offices is 3851 West Hamlin Road, Rochester Hills, Michigan 48309.  This Amendment No. 1 to Schedule 13D relates to the Issuer's Common Stock, par value $0.0001 per share (the “Shares”).  
         
         

     

    Item 2. Identity and Background.  

     

      (a), (f) The persons filing this statement are: (i) Sansone Advisors, LLC, a Delaware limited liability company (“Sansone Advisors”); (ii) Sansone Capital Management, LLC, a Delaware limited liability company (“Sansone Capital Management”); (iii) Sansone Partners, LP, a Delaware limited partnership (“Sansone Partners”); and (iv) Christopher Sansone, a United States citizen (“Mr. Sansone”, and collectively with Sansone Advisors, Sansone Capital Management and Sansone Partners, the “Reporting Persons”).    
           
      (b), (c) Sansone Advisors is principally engaged in the business of providing investment management services to its pooled investment vehicle clients, including Sansone Partners (collectively, the “Sansone Funds”).  Sansone Capital Management serves as the general partner of the Sansone Funds.  Sansone Partners is principally engaged in the business of investing in securities.  Mr. Sansone is the managing member of Sansone Advisors and Sansone Capital Management.  The principal business address of the Reporting Persons is 151 Bodman Place, Suite 100, Red Bank, New Jersey 07701.  
           
      (d) None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).  
           
      (e) None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.  
         

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.  
         
     

    The funds for the purchase of the 1,612,194 Shares beneficially owned by Sansone Advisors came from the working capital of the Sansone Funds. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

     

    The funds for the purchase of the 1,612,194 Shares beneficially owned by Sansone Capital Management came from the working capital of the Sansone Funds. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

     

    The funds for the purchase of the 1,464,916 Shares directly owned by Sansone Partners came from its working capital. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

     

    The funds for the purchase of the 1,670,543 Shares beneficially owned by Mr. Sansone came from: (i) the working capital of the Sansone Funds; and (ii) the exercise of stock options received by Mr. Sansone in connection with his prior service on the Issuer’s board of directors (the “Board”). No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

     
         

     

     

    Item 4. Purpose of Transaction.  
         
     

    The Shares beneficially owned by the Reporting Persons were acquired for investment in the ordinary course of the Reporting Persons’ investment activities.

     

    This Schedule 13D/A is being filed to report: (i) that, effective as of the Issuer’s 2023 annual meeting of its stockholders on May 16, 2023, Mr. Sansone no longer serves as a member of the Board; and (ii) a change in the Reporting Persons’ respective beneficial ownership percentages.

     

    Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own in open-market transactions or privately negotiated transactions. The Reporting Persons may also communicate with the Issuer’s management, the Board and other holders of Shares from time to time.

     
         

     

     

     

    Item 5. Interest in Securities of the Issuer.  
         
      (a) - (d)

    As of the date hereof, Sansone Advisors may be deemed to be the beneficial owner of 1,612,194 Shares, constituting 7.6% of the Shares, based upon 21,183,526 Shares outstanding as of the date hereof. Sansone Advisors has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 1,612,194 Shares. Sansone Advisors has the sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition of 1,612,194 Shares.

     

    As of the date hereof, Sansone Capital Management may be deemed to be the beneficial owner of 1,612,194 Shares, constituting 7.6% of the Shares, based upon 21,183,526 Shares outstanding as of the date hereof. Sansone Capital Management has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 1,612,194 Shares. Sansone Capital Management has the sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition of 1,612,194 Shares.

     

    As of the date hereof, Sansone Partners may be deemed to be the beneficial owner of 1,464,916 Shares, constituting 6.9% of the Shares, based upon 21,183,526 Shares outstanding as of the date hereof. Sansone Partners has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 1,464,916 Shares. Sansone Partners has the sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition of 1,464,916 Shares.

     

    As of the date hereof, Mr. Sansone may be deemed to be the beneficial owner of 1,670,543 Shares, constituting 7.9% of the Shares, based upon 21,183,526 Shares outstanding as of the date hereof. Mr. Sansone has the sole power to vote or direct the vote of 58,349 Shares and the shared power to vote or direct the vote of 1,612,194 Shares. Mr. Sansone has the sole power to dispose or direct the disposition of 58,349 Shares and the shared power to dispose or direct the disposition of 1,612,194 Shares.

     

    There have been no transactions by the Reporting Persons in the Shares during the past 60 days.

     
     

     

    (e)

     

    N/A

     

     

     

     

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.  
         
     

    The information set forth in Item 4 above is incorporated by reference in its entirety in this Item 6. The Reporting Persons do not have any contract, arrangement, understanding or relationship with any person with respect to securities of the Issuer that is not described in Item 4 above and/or incorporated herein by reference.

     

     

     

     

    Item 7. Material to be Filed as Exhibits.  

     

     

    Exhibit A:  Joint Filing Agreement

     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  November 29, 2023   Sansone Advisors, LLC*
         
        By: /s/ Christopher Sansone
        Name:  Christopher Sansone
        Title:   Managing Member

     

        Sansone Capital Management, LLC*
         
        By: /s/ Christopher Sansone
        Name:  Christopher Sansone
        Title:   Managing Member

     

       

    Sansone Partners, LP*

     

    By: Sansone Capital Management, LLC

    Its general partner

         
        By: /s/ Christopher Sansone
        Name:  Christopher Sansone
        Title:   Managing Member

     

        Christopher Sansone*
         
        By: /s/ Christopher Sansone
         
         

    * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interests therein, and this report shall not be deemed an admission that such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Exhibit A

     

     

    AGREEMENT

     

    The undersigned agree that this Amendment No. 1 to Schedule 13D, dated November 29, 2023, relating to the Common Stock, par value $0.0001 per share, of InfuSystem Holdings, Inc. shall be filed on behalf of the undersigned.

     

    Dated:  November 29, 2023   Sansone Advisors, LLC
         
        By: /s/ Christopher Sansone
        Name:  Christopher Sansone
        Title:   Managing Member

     

        Sansone Capital Management, LLC
         
        By: /s/ Christopher Sansone
        Name:  Christopher Sansone
        Title:   Managing Member

     

       

    Sansone Partners, LP

     

    By: Sansone Capital Management, LLC

    Its general partner

         
        By: /s/ Christopher Sansone
        Name:  Christopher Sansone
        Title:   Managing Member

     

        Christopher Sansone
         
        By: /s/ Christopher Sansone
         
         

     

     

     

    Get the next $INFU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INFU

    DatePrice TargetRatingAnalyst
    7/22/2025$12.00Buy
    Roth Capital
    9/26/2024$13.00Buy
    B. Riley Securities
    More analyst ratings

    $INFU
    SEC Filings

    View All

    SEC Form 10-Q filed by InfuSystems Holdings Inc.

    10-Q - InfuSystem Holdings, Inc (0001337013) (Filer)

    8/5/25 5:17:03 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystems Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

    8/5/25 6:29:43 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

    7/29/25 4:28:01 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Leadership Updates

    Live Leadership Updates

    View All

    InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

    The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping down as the Company's Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company's President and Chief Operating Officer, and a member of the Company's board of directors, will assume the role of Chief Executive Officer effective May 19

    4/1/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Appoints Ronald Hundzinski to the Board of Directors

    InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and

    11/18/24 9:15:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors

    InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has

    9/23/22 4:05:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on InfuSystem with a new price target

    Roth Capital initiated coverage of InfuSystem with a rating of Buy and set a new price target of $12.00

    7/22/25 7:53:05 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on InfuSystem with a new price target

    B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00

    9/26/24 7:35:18 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Northland Capital initiated coverage on InfuSystem with a new price target

    Northland Capital initiated coverage of InfuSystem with a rating of Outperform and set a new price target of $27.00

    4/26/21 8:42:07 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shuda Scott disposed of 2,242 shares and sold $55,622 worth of shares (5,752 units at $9.67), decreasing direct ownership by 8% to 94,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    8/22/25 5:33:54 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    New insider Sviokla John J claimed ownership of 10,000 shares (SEC Form 3)

    3 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    6/16/25 7:38:02 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Director Eichenbaum Kenneth D. bought $10,360 worth of shares (2,000 units at $5.18), increasing direct ownership by 50% to 6,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/28/25 4:24:49 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InfuSystem Reports Second Quarter 2025 Financial Results

    Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0

    8/5/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

    Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the

    7/29/25 4:30:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Reports First Quarter 2025 Financial Results

    Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

    5/8/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eichenbaum Kenneth D. bought $10,360 worth of shares (2,000 units at $5.18), increasing direct ownership by 50% to 6,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/28/25 4:24:49 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Director Hundzinski Ronald T bought $30,450 worth of shares (5,000 units at $6.09) (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/20/25 6:54:45 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    President and COO Lachance Carrie bought $18,987 worth of shares (3,132 units at $6.06), increasing direct ownership by 2% to 190,212 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/19/25 7:58:16 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    12/9/24 6:38:13 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    12/6/24 5:07:04 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    9/24/24 2:06:02 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Financials

    Live finance-specific insights

    View All

    InfuSystem Reports Second Quarter 2025 Financial Results

    Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0

    8/5/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

    Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the

    7/29/25 4:30:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Reports First Quarter 2025 Financial Results

    Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

    5/8/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care